Chronic Dry Eye Links
The links below will take you to independent sites that will open in a new browser window.
To return to RESTASIS.com, simply close the new browser window.
- American Academy of Ophthalmology
- American Academy of Optometry
- American Optometric Association
- Association for Research in Vision and Ophthalmology
- Eye Search
- iVillage
- MedlinePlus
- National Eye Institute
- National Women's Health Resource Center
- Sjögren’s Syndrome Foundation
- Tear Film & Ocular Surface Society
- The Schepens Eye Research Institute
- The Wilmer Eye Institute
- WebMD
Articles
- Dealing With Dry Eye (PDF)
- Posted: August 23, 2005.
- FDA Consumer magazine (May-June 2005 issue),
- by Michelle Meadows.
- FDA article providing an overview of dry eye and treatment options, which include artificial tears, RESTASIS®, and punctal plugs.
© 2007 Allergan, Inc. All rights reserved | Privacy Statement | FAQs | Terms of Use | Site Map
This information is intended for residents of the United States. ® and ™ marks owned by Allergan, Inc.
RESTASIS® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
Important Safety Information:
RESTASIS® is contraindicated in patients with active ocular infections and has not been studied in patients with a history of herpes keratitis.
The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).
Please see full prescribing information for RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%.